Nventa assembles group of international experts for its Clinical and Scientific Advisory Board
Nventa Biopharmaceuticals Corporation announced that it has assembled a Clinical and Scientific Advisory Board. The Board will be instrumental in providing strategic and scientific guidance on the Company's development programs, including its lead HspE7 clinical program for human papillomavirus (HPV)-related diseases, and future CoVal(TM) fusion development programs. The following group of international scientists and clinicians represents years of experience in the fields of immunology, HPV biology, vaccine development, and clinical research in HPV-related diseases including cervical dysplasia and cancer:
Ian Hector Frazer, PhD: Director, Centre for Immunology and Cancer Research, University of Queensland, Australia. Dr. Frazer's research into HPV pathogenesis and prevention resulted in discovery and development of the virus like particle technology enabling the two vaccines recently licensed to help prevent cervical cancer.
W. Martin Kast, PhD: Walter A. Richter Cancer Research Chair; Professor of Molecular Microbiology & Immunology and Obstetrics & Gynecology; Norris Comprehensive Cancer Center, University of Southern California. Dr. Kast's research is focused in the areas of therapeutic vaccine development for the treatment of prostate cancer and HPV-linked cancers such as cervical cancer.
Myron J. Levin, MD: Professor of Pediatrics and Medicine, University of Colorado Health Sciences Center. Dr. Levin's primary research focus is in pediatric infectious diseases and the design of both prophylactic and therapeutic vaccines.
Jeffrey Weber, MD, PhD: Professor, Department of Interdisciplinary Oncology and Head, Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center in Florida. Dr. Weber's research and clinical focus is on understanding how to stimulate the body's immune system to eliminate various cancers, including melanoma and HPV-induced cervical lesions.
T.-C. Wu, MD, PhD: Professor of Pathology, Oncology, Obstetrics and Gynecology, The Johns Hopkins University School of Medicine; Professor of Molecular Microbiology and Immunology, The Johns Hopkins University, Bloomberg School of Public Health; Research Director of Gynecologic Pathology; Pathologist, The Johns Hopkins Hospital. Dr. Wu's research has been in the area of vaccine development for the treatment of cervical lesions caused by HPV.
Other news from the department people
